Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Knowns and the Unknowns

Sunir Garg, MD

May 11, 2022

While noting the considerable amount of time that has passed since anti-VEGF therapy became available for exudative (wet) age-related macular degeneration (AMD), Sunir Garg, MD, reflects upon the current knowns and unknowns regarding this frequently disabling disorder. Figuring among the top knowns are, first, the importance of early detection, a central factor in improving patient outcomes. This is facilitated both in terms of clinical encounters and at-home testing with devices such as the Amsler grid and a forthcoming home-based version of optical coherence tomography (OCT).

Second of these recognitions is the crucial role of continuous treatment, vital in preventing extended gaps in therapy and avoiding the perils of undertreatment, which threaten to always undermine therapeutic gains.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Knowns and the Unknowns - Medscape - May 11, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.